Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) (NCT04305769)
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: a Randomized, Double-blind, Placebo-controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident cases of uncomplicated C. difficile infection (CDI) in hospitalized, or outpatient, persons aged 18 or older. The investigators hypothesis is that alanyl-glutamine supplementation will decrease recurrence and mortality from CDI and these outcomes will be associated with improvement of inflammatory markers and restoration of intestinal microbiota function.
Who can join: Review the eligibility criteria below.
Location: UVA Health Systems — Charlottesville, Virginia
Age range: 18 Years to 105 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- UVA Health Systems — Charlottesville, Virginia
- Carilion Clinic — Roanoke, Virginia
📞 Contact the Study Coordinator
Phone: (434) 270-1082
Email: CA6T@hscmail.mcc.virginia.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clostridioides Difficile Infection
- LMN-201 for Prevention of C. Difficile Infection Recurrence — Escondido, California
- Evaluation of GeoHAI Implementation — Columbus, Ohio
- Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy — Milwaukee, Wisconsin
- Lifestyle and Recurrent Clostridioides Difficile Infection (CDI) — Ann Arbor, Michigan
- Secondary Prevention of Clostridioides Difficile Using Vancomycin — Montreal, Quebec
Explore by condition: All Clostridioides Difficile Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.